Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab

Denosumab is a human monoclonal antibody (IgG2) that binds to RANK ligand (RANKL). It reduces osteoclasts and thereby decreases bone resorption and cancer-induced bone destruction.